Clinical trial design, biomarkers and end points in metabolic and alcohol-related liver disease.

Metabolic and alcohol-related liver disease (MetALD) is a newly defined entity within the spectrum of steatotic liver disease, characterized by the interplay of cardiometabolic risk factors and alcohol consumption. The evolving epidemiology and complex pathophysiology of MetALD present unique challe...

Full description

Bibliographic Details

Published in:	Nature Reviews Gastroenterology & Hepatology Vol. 22; no. 12; pp. 866 - 885
Main Authors:	Diaz, Luis Antonio, Thiele, Maja, Louvet, Alexandre, Lee, Brian P., Ajmera, Veeral, Tavaglione, Federica, Hsu, Cynthia L., Huang, Daniel Q., Pose, Elisa, Bataller, Ramon, McClain, Craig, Mellinger, Jessica, Tincopa, Monica, Mitchell, Mack C., Ratziu, Vlad, Rinella, Mary E., Sarin, Shiv K., Shah, Vijay H., Szabo, Gyongyi, Wong, Vincent Wai-Sun
Format:	Journal Article
Published:	Springer Nature Dec2025
Online Access:	View this record in EBSCOhost